December 9th 2024
Here's some of what is coming soon to NeurologyLive® this week.
Get direct access to interviews with experts, as well as the latest data and clinical news updates, straight from the conference floor in Los Angeles.
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Burst CME: Optimizing Therapy in Parkinson’s Disease
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
View More
Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders
View More
Interim Analysis Highlights Long-Term Safety of Azetukalner for Focal Epilepsy
December 6th 2024In a further date from the ongoing open-label extension of the phase 2b X-TOLE study, results demonstrated that the majority of treatment-emergent adverse events associated with azetukalner were mild or moderate.
FDA Grants NS-050/NCNP-03 Rare Pediatric Disease Designation in Duchenne Muscular Dystrophy
December 5th 2024A recently initiated phase 1/2 trial of NS-050/NCNP-03 will assess patients with Duchenne muscular dystrophy on dystrophin production, muscle strength, mobility, and functional exercise capacity.
Testing Begins for RELIEV-CM2 Study of ShiraTronics Neuromodulation Device in Chronic Migraine
Early data from the pilot RELIEV-CM trial showed significant reductions in headache and migraine days, with 56% of patients showing a 50% reduction in symptoms at 4 weeks, and 100% at 12 weeks.
A Mother’s Fight Against Infantile Spasms: The Power of Instinct and Community
December 4th 2024This story highlights a mother’s journey through her daughter Addie's diagnosis of Tuberous Sclerosis Complex (TSC), emphasizing the critical need for early diagnosis, parental advocacy, and the strength of community support.
NeuroVoices: Martina Bebin, MD, MPA, on Critical Aspects of Infantile Spasms Awareness
The professor of neurology at the University of Alabama at Birmingham Epilepsy Center commented on various topics related to infantile spasms amid Infantile Spasms Awareness Week.
Empowering Patients: Exploring Self-Administration of Rozanolixizumab for Myasthenia Gravis
Rachana K. Gandhi Mehta, MBBS, an assistant professor of neurology at Wake Forest School of Medicine, discussed a new, innovative trial assessing the therapeutic potential of self-administered subcutaneous rozanolixizumab as a treatment for myasthenia gravis.
STATHMIN-Targeting Therapy QRL-201 Enters Dose Range-Finding Phase Following Successful PK Analysis
QRL-201, developed by QurAlis, aims to restore STATHMIN-2 (STMN2) expression, a key protein for neural repair, which is significantly reduced in patients with ALS.
Brenig Therapeutics Initiates First-in-Human Trial of LRRK2 Inhibitor BT-267 for Parkinson Disease
To date, BT-267 shows strong potential as a best-in-class LRRK2 inhibitor for Parkinson disease, with a superior safety profile, excellent pharmacokinetics, and innovative development leveraging advanced technologies and biomarker modeling.
Anavex Submits Marketing Authorization Application for Blarcamesine in Alzheimer Disease in the EU
The application is based on a large-scale phase 3 study in which blarcamesine demonstrated a significant decline in disease progression compared with placebo over a 48-week period.